| dc.contributor.author | Saribas, Zeynep | |
| dc.contributor.author | Sener, Burcin | |
| dc.contributor.author | Haznedaroglu, Ibrahim C. | |
| dc.contributor.author | Hascelik, Gulsen | |
| dc.contributor.author | Kirazli, Serafettin | |
| dc.contributor.author | Goker, Hakan | |
| dc.date.accessioned | 2019-12-12T06:26:55Z | |
| dc.date.available | 2019-12-12T06:26:55Z | |
| dc.date.issued | 2010 | |
| dc.identifier.issn | 1895-1058 | |
| dc.identifier.uri | https://doi.org/10.2478/s11536-009-0140-4 | |
| dc.identifier.uri | http://hdl.handle.net/11655/16422 | |
| dc.description.abstract | The aim of this study is to investigate the in vitro antimicrobial activity of Ankaferd Blood StopperA (R) against methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus species, Escherichia coli, Pseudomonas species, Acinetobacter species and Klebsiella species of nosocomial origin. Ankaferd inhibited growth in 72.4% to 100% of the bacteria tested, depending on the type of the isolate. As a result, it can be stated that Ankaferd inhibits the in vitro growth of nosocomial bacteria. This is a novel, important finding since severe hospital infections coexist with many hemostatic disorders, and the use of Ankaferd may increase hemostatic potential in such clinical conditions. | |
| dc.language.iso | en | |
| dc.publisher | Versita | |
| dc.relation.isversionof | 10.2478/s11536-009-0140-4 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | General & Internal Medicine | |
| dc.title | Antimicrobial Activity of Ankaferd Blood Stoppera (R) Against Nosocomial Bacterial Pathogens | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.relation.journal | Central European Journal Of Medicine | |
| dc.contributor.department | Tıbbi Mikrobiyoloji | |
| dc.identifier.volume | 5 | |
| dc.identifier.issue | 2 | |
| dc.identifier.startpage | 198 | |
| dc.identifier.endpage | 202 | |
| dc.description.index | WoS | |
| dc.description.index | Scopus | |
